• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Sedana Medical appoints Mikael Haag as Chief Financial Officer (CFO)

SEDANARegulatory press release27.01.2026 klo 09.00
Discuss
Download the release

Sedana Medical AB (publ) announces the appointment of Mikael Haag as Chief Financial Officer (CFO) and member of the Executive Management Team. Mikael will assume his position no later than July 2026.

Mikael is an accomplished finance executive with more than 20 years of experience and a strong track record as CFO in both publicly listed and private equity-backed growth companies, including SmartOptics Group and Hive Streaming. He has successfully driven improvements in financial performance and brings extensive experience in building and scaling businesses in the United States. Mikael holds dual degrees from the Stockholm School of Economics (Handelshögskolan) and the Royal Institute of Technology (KTH).

“I am very pleased to welcome Mikael to our Executive Management Team,” said Johannes Doll, CEO of Sedana Medical. “His business-oriented mindset and strong focus on performance are an excellent fit with our ambition to further expand our profitable European business while establishing a successful operation in the United States.”

“I am excited to join Sedana Medical at this important stage of the company’s development,” said Mikael Haag. “The combination of a growing, profitable core business and the significant potential in the U.S. market creates a compelling opportunity to scale the company while making a true difference for intensive care patients. I look forward to contributing to Sedana Medical’s continued growth and long-term value creation.”

Sedana Medical’s current CFO, Johan Spetz, will remain in his role until June 2026 to ensure a smooth transition and handover.

For additional information, please contact:


Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
ir@sedanamedical.com

About Sedana Medical


Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.

Attachments


Sedana Medical appoints Mikael Haag as Chief Financial Officer (CFO)